AN2 Therapeutics, Inc. (ANTX) vs Cue Biopharma, Inc. (CUE)
A side-by-side comparison of AN2 Therapeutics, Inc. and Cue Biopharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ANTX
AN2 Therapeutics, Inc.
$5.18HealthcareDelayed quote: Oct 6, 2026, 12:09 PM EDT
CUE
Cue Biopharma, Inc.
$23.85HealthcareDelayed quote: Oct 6, 2026, 12:09 PM EDT
Total return — ANTX vs CUE
growth of $100 · dividends reinvested · last 5yANTX -63.6% (-18.3%/yr)CUE -83.8% (-30.5%/yr)ANTX compounded faster over this window
ANTX CUE
ANTX vs CUE: by the numbers
- •ANTX is the larger company ($187M vs $173M market cap).
- •Both run net losses; ANTX's is the smaller (0.00% vs -435.83% net margin).
Metrics side by side
Valuation
| Metric | ANTX | CUE |
|---|---|---|
| P/S ratio | N/A | 4.60 |
| P/B ratio | 2.46 | 75.00 |
Profitability
| Metric | ANTX | CUE |
|---|---|---|
| Gross margin | 0.00% | 99.69% |
| Operating margin | 0.00% | -96.56% |
| Net margin | 0.00% | -435.83% |
| ROE | -47.78% | -7104.24% |
| ROIC | -51.01% | -1039.56% |
Growth (annualized)
| Metric | ANTX | CUE |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 47.08% |
| Total return CAGR (5Y) | N/A | -42.42% |
Go deeper
Dig into the metrics
AN2 Therapeutics ROECue Biopharma ROEAN2 Therapeutics operating marginCue Biopharma operating marginAN2 Therapeutics revenue growthCue Biopharma revenue growthAN2 Therapeutics free cash flowCue Biopharma free cash flow
AN2 Therapeutics & Cue Biopharma appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.